BRPI0806257A2 - método de tratamento, e, uso de uma composição imunoterapêutica - Google Patents
método de tratamento, e, uso de uma composição imunoterapêutica Download PDFInfo
- Publication number
- BRPI0806257A2 BRPI0806257A2 BRPI0806257-9A BRPI0806257A BRPI0806257A2 BR PI0806257 A2 BRPI0806257 A2 BR PI0806257A2 BR PI0806257 A BRPI0806257 A BR PI0806257A BR PI0806257 A2 BRPI0806257 A2 BR PI0806257A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- immunotherapeutic composition
- immune
- radiotherapy
- chemotherapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
MéTODO DE TRATAMENTO, E, USO DE UMA COMPOSIçãO IMUNOTERAPêUTICA. Uma terapia combinada, compreendendo uma imunoterapia com base em um antígeno de tumor ou um seu derivado imunológico e pelo menos um outro tratamento para câncer, tal como quimioterapia, radioterapia e/ou cirurgia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0700284.3A GB0700284D0 (en) | 2007-01-08 | 2007-01-08 | Combination therapy |
PCT/EP2008/050133 WO2008084040A1 (en) | 2007-01-08 | 2008-01-08 | Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0806257A2 true BRPI0806257A2 (pt) | 2011-08-30 |
Family
ID=37801846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0806257-9A BRPI0806257A2 (pt) | 2007-01-08 | 2008-01-08 | método de tratamento, e, uso de uma composição imunoterapêutica |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100008980A1 (pt) |
EP (1) | EP2099470A1 (pt) |
JP (1) | JP2010515670A (pt) |
KR (1) | KR20090099011A (pt) |
CN (1) | CN101578105A (pt) |
AU (1) | AU2008204526A1 (pt) |
BR (1) | BRPI0806257A2 (pt) |
CA (1) | CA2674315A1 (pt) |
EA (1) | EA200900735A1 (pt) |
GB (1) | GB0700284D0 (pt) |
MX (1) | MX2009007295A (pt) |
WO (1) | WO2008084040A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA020617B1 (ru) * | 2009-05-27 | 2014-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Конструкции casb7439 |
US20130031794A1 (en) | 2011-08-05 | 2013-02-07 | Duff Jr Ronald Richard | RAZOR BLADES WITH ALUMINUM MAGNESIUM BORIDE (AlMgB14)-BASED COATINGS |
RU2014122867A (ru) * | 2011-12-22 | 2016-02-20 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
CZ298364B6 (cs) * | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
ATE446106T1 (de) * | 2001-11-29 | 2009-11-15 | Dandrit Biotech As | Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier |
JP2009538286A (ja) * | 2006-05-26 | 2009-11-05 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 癌に対するワクチン接種 |
-
2007
- 2007-01-08 GB GBGB0700284.3A patent/GB0700284D0/en not_active Ceased
-
2008
- 2008-01-08 BR BRPI0806257-9A patent/BRPI0806257A2/pt not_active IP Right Cessation
- 2008-01-08 MX MX2009007295A patent/MX2009007295A/es not_active Application Discontinuation
- 2008-01-08 EA EA200900735A patent/EA200900735A1/ru unknown
- 2008-01-08 JP JP2009544419A patent/JP2010515670A/ja active Pending
- 2008-01-08 CN CNA2008800019176A patent/CN101578105A/zh active Pending
- 2008-01-08 KR KR1020097016573A patent/KR20090099011A/ko not_active Application Discontinuation
- 2008-01-08 US US12/520,882 patent/US20100008980A1/en not_active Abandoned
- 2008-01-08 EP EP08707835A patent/EP2099470A1/en not_active Ceased
- 2008-01-08 WO PCT/EP2008/050133 patent/WO2008084040A1/en active Application Filing
- 2008-01-08 AU AU2008204526A patent/AU2008204526A1/en not_active Abandoned
- 2008-01-08 CA CA002674315A patent/CA2674315A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008084040A8 (en) | 2008-08-28 |
GB0700284D0 (en) | 2007-02-14 |
WO2008084040A1 (en) | 2008-07-17 |
MX2009007295A (es) | 2009-07-14 |
KR20090099011A (ko) | 2009-09-18 |
AU2008204526A1 (en) | 2008-07-17 |
JP2010515670A (ja) | 2010-05-13 |
CN101578105A (zh) | 2009-11-11 |
EP2099470A1 (en) | 2009-09-16 |
CA2674315A1 (en) | 2008-07-17 |
EA200900735A1 (ru) | 2010-02-26 |
US20100008980A1 (en) | 2010-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
MX2019011148A (es) | Metodos de tratamiento. | |
BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
EP3895725A3 (en) | A method for treating tumor by using recombinant interferon with changed spatial configuration | |
MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
MX2013006758A (es) | Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. | |
BR112018011177A2 (pt) | conjugados de citarabina para terapia de câncer | |
MX2020001727A (es) | Terapia de combinacion. | |
AR104484A1 (es) | Anticuerpos anti-psma como agentes terapéuticos | |
CO6382138A2 (es) | N-cadherina: blanco para diagnosis y terapia de cáncer | |
CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
CO2019003865A2 (es) | Proteína terapéutica | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 4A ANUIDADE. |